When low cost cards can assist relieve the burden of higher drug costs from the temporary, they don't tackle the systemic troubles driving up prescription charges during the U.S. Broader plan changes could tackle the foundation leads to of increasing drug costs, such as lack of transparency in pricing as well as function of intermediaries like PBMs